518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors

Autor:	Babar Bashir, M. Rosario, Graeme Hodgson, L. Zhu, H. Jolin, Erika Hamilton, Dejan Juric, Debra L. Richardson, V. Klimek, M. Kelly, N. Ke, D. Roth, Kyri Papadopoulos, Geoffrey I. Shapiro, C. Madigan, S.H. Henry, Anthony D'Ippolito, Manish Sharma
Rok vydání:	2021
Předmět:	Oncology Tolerability business.industry Medicine In patient Hematology Cyclin-dependent kinase 7 Pharmacology business
Zdroj:	Annals of Oncology. 32:S587-S588
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4be157b4da6ad970b838d01ced733ef5 https://doi.org/10.1016/j.annonc.2021.08.1040 Zobrazit plný text záznamu